On Jan. 17, Moffitt Cancer Center officials delivered the final report of the institution’s internal investigation to the Florida legislature, alleging that top leaders and researchers at the cancer center had opened personal bank accounts in China and received unreported personal payments and other research support.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
